Sauder Schelkopf is investigating potential litigation against Aurobindo Pharma USA, maker of valsartan, a blood pressure medication. It was reported that Aurobindo Pharma recently recalled 80 lots of Amlodipine Valsartan Tablets USP, Valsartan HCTZ Tablets, USP and Valsartan Tablets USP with expiration dates ranging from May 2019 to March 2021 because of concerns that the tablets could be contaminated with a cancer-causing agent. The U.S. Food and Drug Administration reported that traces of N-nitrosodimethylamine (NDMA), a “probable human carcinogen,” were found in the active ingredient valsartan in the recalled products. A total list of the recalled product can be found here.
Sauder Schelkopf has a nationally recognized litigation practice with significant experience representing individuals throughout the country. The attorneys at Sauder Schelkopf have recovered hundreds of millions of dollars on behalf of our clients.
We Want to Hear from You
If you or a loved one has taken one of the recalled lots of valsartan, please submit your information below.